HCR Monthly Blog

America’s “Great Generic Wars” and the Canadian-European Trade Agreement

August 26th, 2014 Tom Norton

As a young pharmaceutical manager, I became involved in America’s “Great Generic Wars” in the late 1970’s. It was an epic struggle between the U.S. brand name manufacturers and numerous generic drug producers that wanted to make generics widely available on the U.S. market. Depending on your point of view, the wars were fought over read more

 

The US Rx Tax Exodus: Is Something “Probably Wrong” with Our System?

July 9th, 2014 Tom Norton

As I read the latest reports of yet another big US Rx firm, this time AbbVie, trying to pull off a “tax inversion” takeover of the Irish-based Shire, I couldn’t help but wonder, what the heck is going on here? Right now, it feels like most major US corporations, especially pharmas, are literally running away read more

 

What Does ‘Off Label’ Mean in 2014?

June 12th, 2014 Tom Norton

Years ago, while sitting in an Rx company lunch room, I was listening to one of the company’s top sales reps discuss the commercial progress a recently launched prescription was making. The rep said that the product was selling “OK” under its FDA approved, indicated therapeutic area. However, he quietly said, “It’s not the approved read more

 

Obamacare’s “Unacceptable” Rx Copays

May 28th, 2014 Tom Norton

We are now approaching the six month point in the implementation of the new Obamacare program. It’s senseless to go into the good, bad and ugly of this new program. While much of the concept continues to be thrashed about in the political arena, in terms of actual medical results the truth of what Obamacare read more